Moderna Revenue 2017-2021 | MRNA

Moderna annual/quarterly revenue history and growth rate from 2017 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Moderna revenue for the quarter ending June 30, 2021 was $4.354B, a 6398.51% increase year-over-year.
  • Moderna revenue for the twelve months ending June 30, 2021 was $7.019B, a 6515.77% increase year-over-year.
  • Moderna annual revenue for 2020 was $0.803B, a 1234.34% increase from 2019.
  • Moderna annual revenue for 2019 was $0.06B, a 55.42% decline from 2018.
  • Moderna annual revenue for 2018 was $0.135B, a 34.38% decline from 2017.
Moderna Annual Revenue
(Millions of US $)
2020 $803
2019 $60
2018 $135
2017 $206
2016 $108
Moderna Quarterly Revenue
(Millions of US $)
2021-06-30 $4,354
2021-03-31 $1,937
2020-12-31 $570
2020-09-30 $158
2020-06-30 $67
2020-03-31 $8
2019-12-31 $14
2019-09-30 $17
2019-06-30 $13
2019-03-31 $16
2018-12-31 $35
2018-09-30 $42
2018-06-30 $29
2018-03-31 $29
2017-12-31
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $173.624B $0.803B
Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA- 2752 for Relapsed/Refractory solid tumors malignancies. Moderna Inc. is based in Cambridge, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29